AU1432897A - Use of galanthamine in the preparation of novel drugs - Google Patents

Use of galanthamine in the preparation of novel drugs

Info

Publication number
AU1432897A
AU1432897A AU14328/97A AU1432897A AU1432897A AU 1432897 A AU1432897 A AU 1432897A AU 14328/97 A AU14328/97 A AU 14328/97A AU 1432897 A AU1432897 A AU 1432897A AU 1432897 A AU1432897 A AU 1432897A
Authority
AU
Australia
Prior art keywords
galanthamine
preparation
novel drugs
drugs
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU14328/97A
Inventor
Werner Frantsits
Martin Alois Hermann Mucke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanochemia Ltd
Original Assignee
Sanochemia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanochemia Ltd filed Critical Sanochemia Ltd
Publication of AU1432897A publication Critical patent/AU1432897A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU14328/97A 1996-01-26 1997-01-27 Use of galanthamine in the preparation of novel drugs Abandoned AU1432897A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0014996A AT402691B (en) 1996-01-26 1996-01-26 USE OF GALANTHAMINE FOR PRODUCING MEDICINAL PRODUCTS FOR TREATING TRISOMY 21 OR RELATED TRISOMY SYNDROME
AT149/96 1996-01-26
PCT/AT1997/000011 WO1997026887A1 (en) 1996-01-26 1997-01-27 Use of galanthamine in the preparation of novel drugs

Publications (1)

Publication Number Publication Date
AU1432897A true AU1432897A (en) 1997-08-20

Family

ID=3482843

Family Applications (1)

Application Number Title Priority Date Filing Date
AU14328/97A Abandoned AU1432897A (en) 1996-01-26 1997-01-27 Use of galanthamine in the preparation of novel drugs

Country Status (4)

Country Link
EP (1) EP0876147A1 (en)
AT (1) AT402691B (en)
AU (1) AU1432897A (en)
WO (1) WO1997026887A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032199A1 (en) * 1998-12-01 2000-06-08 Sanochemia Pharmazeutika Aktiengesellschaft Use of galanthamine and galanthamine derivatives in the case of acute functional brain damage
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20100168081A1 (en) * 2005-08-11 2010-07-01 Adriana Di Polo Galantamine as a neuroprotective drug for retinal ganglion cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE4010079A1 (en) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF ALCOHOLISM
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
US5177070A (en) * 1991-11-15 1993-01-05 Ciba-Geigy Corporation Method of treating physiologic male erectile impotence
DE4301783C1 (en) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermal system per admin. of galanthamine - esp. for treatment of Alzheimer's disease and alcohol addiction
DE4301782C1 (en) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Use of galanthamine to treat nicotine addiction
US5428159A (en) * 1994-04-08 1995-06-27 Ciba-Geigy Corporation Method of manufacture of (-)-galanthamine in high yield and purity substantially free of epigalanthamine
DE19509663A1 (en) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Process for the isolation of galanthamine

Also Published As

Publication number Publication date
AT402691B (en) 1997-07-25
WO1997026887A1 (en) 1997-07-31
EP0876147A1 (en) 1998-11-11
ATA14996A (en) 1996-12-15

Similar Documents

Publication Publication Date Title
AU1618697A (en) Novel compounds and pharmaceutical use thereof
AU3890297A (en) Herbal formulation and therapeutic uses therefor
IL116851A0 (en) 3-arylidene-2-oxindole derivatives their preparation and use
AU3102097A (en) Spiro-piperidine derivatives and their use as therapeutic agents
IL118825A (en) Substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane derivatives their preparation and use
AU2505795A (en) 1-arylpyrimidine derivatives and pharmaceutical use thereof
IL120124A0 (en) Heteroaryl-oxazolidinones their preparation and use
AU5136998A (en) Medicinal composition
IL118442A0 (en) Triazolymethyl-cyclopentanols their preparation and use
IL118441A0 (en) Triazolymethyl-oxiranes their preparation and use
AU4204697A (en) Tetrahydroisoquinoline derivatives and their pharmaceutical use
AU7401598A (en) Epoxide-amine dendrimers and the preparation and use thereof
GB9715490D0 (en) Pharmaceutical preparation
EP0907644A4 (en) Pharmaceutical preparation
AU3268197A (en) Spiro-piperidine derivatives and their use as therapeutic agents
IL118443A0 (en) Cycloalkane-benzylidene derivatives their preparation and use
IL123092A0 (en) Pyrazol-4-ylbenzoyl derivatives their preparation and use
HRP960117B1 (en) Bicyclic compounds, their preparation and use in pharmaceutical preparations
AU2529799A (en) Benzofuran-4-carboxamides and their therapeutic use
AU1475595A (en) Pharmaceutical preparation
AU5416898A (en) Cisplatinum comprising pharmaceutical
AU691677B2 (en) Tetrahydroisoquinoline derivative and medicinal preparation containing the same
AU1432897A (en) Use of galanthamine in the preparation of novel drugs
IL118444A0 (en) Mercapto-triazolyl-silanes their preparation and use
IL122686A0 (en) Benzylhydroxylamines their preparation and use